Active Ingredient History
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenoma, Liver Cell (Phase 1/Phase 2)
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Choriocarcinoma (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gestational Trophoblastic Disease (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Liver Neoplasms (Phase 2)
Liver Neoplasms, Experimental (Phase 1/Phase 2)
Lung Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 3)
Trophoblastic Tumor, Placental Site (Phase 2)
Ureteral Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue